UM-164
中文名称 | UM-164 |
---|---|
中文同义词 | 2-[[6-[4-(2-羟基乙基)-1-哌嗪基]-2-甲基-4-嘧啶基]氨基]-N-[2-甲基-5-[[3-(三氟甲基)苯甲酰基]氨基]苯基]-5-噻唑甲酰胺;化合物UM-164;2-((6-(4-(2-羟乙基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)-N-(2-甲基-5-(3-(三氟甲基)苯甲酰氨基)苯基)噻唑-5-甲酰胺 |
英文名称 | 903564-48-7 |
英文同义词 | UM-164;DAS-DFGO-II;CS-2793;UM164;UM-164;UM 164;UM-164 (DAS-DFGO-II);5-Thiazolecarboxamide, 2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-;p38 MAPK,Autophagy,UM-164,Src,UM 164,inhibit,Inhibitor;2-((6-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)thiazole-5-carboxamide |
CAS号 | 903564-48-7 |
分子式 | C30H31F3N8O3S |
分子量 | 640.68 |
EINECS号 | |
相关类别 | 标准品 |
Mol文件 | 903564-48-7.mol |
结构式 |
UM-164 性质
密度 | 1.433±0.06 g/cm3(Predicted) |
---|---|
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:5mg/mL |
形态 | 结晶固体 |
酸度系数(pKa) | 11.40±0.70(Predicted) |
颜色 | 白色至米白色 |
p38α
|
p38β
|
c-Src 2.7 nM (Kd) |
In biochemical assays, UM-164 is a highly potent inhibitor of c-Src with a binding constant comparable with Dasatinib (UM-164 K d =2.7 nM, Dasatinib K d =0.7 nM). To confirm that UM-164 is capable of inhibiting the activation of c-Src in vitro, the effect of UM-164 is examined on the c-Src autophosphorylation in two TNBC cell lines (MDA-MB 231 and SUM 149). Inhibition of c-Src autophosphorylation is detected in a concentration- and a time-dependent manner. At 120 minutes, complete abrogation of c-Src autophosphorylation is observed at 50 nM, demonstrating that UM-164 is a potent c-Src inhibitor in vitro. Flow cytometry experiments demonstrate that UM-164 treatment of MDA-MB 231 and SUM 149 increased the proportion of G 0 -G 1 cells by 25% and 28%, respectively, and concurrently decreased the fraction of S cells by 16% and 19%, respectively.
A xenograft study is performed using NCr/nude mice implanted with MDA-MB 231 and SUM 149 cell lines. Once the tumors become palpable, the mice are randomized into control and treatment groups. Mice are injected intraperitoneally with either drug (10 and 20 mg/kg in both xenograft studies; a 15 mg/kg dose is added to the SUM 149 xenograft studies) or vehicle every other day (n=5 for each group). At the selected doses of UM-164, there is no significant weight loss or gross abnormalities observed in the treated animals, even after 52 days of treatment. However, tumor growth is significantly inhibited in both the 10 mg/kg and 20 mg/kg dose groups compared with the vehicle-treated group (P<0.026 and P<0.004, respectively).
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-112182 | UM-164 | 1 mg | 323元 | |
2024/08/19 | HY-112182 | UM-164 UM-164 | 903564-48-7 | 5mg | 850元 |